We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.65B
AUM Growth
-$277M
Cap. Flow
-$110M
Cap. Flow %
-4.17%
Top 10 Hldgs %
67.67%
Holding
75
New
11
Increased
7
Reduced
10
Closed
16
Avg Time Held Equity + Options
6.2 quarters
Top 10 Avg Time Held Equity + Options
6.3 quarters
Top 20 Avg Time Held Equity + Options
8.1 quarters
Avg Time Held Equity only
6.7 quarters
Top 10 Avg Time Held Equity only
6.3 quarters
Top 20 Avg Time Held Equity only
8.1 quarters

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.4M
2
SWTX icon
SpringWorks Therapeutics
SWTX
+$54.5M
3
QURE icon
uniQure
QURE
+$29.4M
4
ZYME icon
Zymeworks
ZYME
+$22.2M
5
XNCR icon
Xencor
XNCR
+$18.7M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$51.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$44.6M
3
NUVB icon
Nuvation Bio
NUVB
+$44M
4
PCVX icon
Vaxcyte
PCVX
+$40.3M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
2 Miscellaneous 5.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
APLS icon
1
DELISTED
Apellis Pharmaceuticals
APLS
$379M 14.35%
11,890,843
– –
2021 Q4
12 quarters
ZYME icon
2
Zymeworks
ZYME
$1.8B
$220M 8.32%
15,028,079
+1,590,606
+12% +$22.2M
2022 Q4
8 quarters
CRNX icon
3
DELISTED
Crinetics Pharmaceuticals
CRNX
$219M 8.29%
4,288,120
– –
2021 Q4
12 quarters
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$13.7B
$210M 7.95%
1,706,469
– –
2023 Q2
6 quarters
PRTA icon
5
Prothena Corp
PRTA
$429M
$160M 6.07%
11,584,280
– –
2018 Q4
24 quarters
XNCR icon
6
Xencor
XNCR
$1.75B
$141M 5.34%
6,144,767
+814,351
+15% +$18.7M
2018 Q4
24 quarters
PFE icon
7
CALL
Pfizer
PFE
$162B
$133M 5.02%
+5,000,000
New +$136M
2024 Q4
0 quarters
ARVN icon
8
Arvinas
ARVN
$447M
$129M 4.88%
6,726,491
– –
2021 Q4
12 quarters
ANAB icon
9
AnaptysBio
ANAB
$1.36B
$104M 3.94%
7,873,448
+78,452
+1% +$1.9M
2019 Q4
20 quarters
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.74B
$93.6M 3.54%
+770,000
New +$94.4M
2024 Q4
0 quarters
JANX icon
11
Janux Therapeutics
JANX
$1.05B
$78.7M 2.98%
1,469,818
– –
2024 Q2
2 quarters
QURE icon
12
uniQure
QURE
$1.48B
$60M 2.27%
+3,400,000
New +$29.4M
2024 Q4
0 quarters
SWTX icon
13
DELISTED
SpringWorks Therapeutics
SWTX
$56.4M 2.13%
+1,560,000
New +$54.5M
2024 Q4
0 quarters
CRSP icon
14
CRISPR Therapeutics
CRSP
$4.84B
$54.7M 2.07%
1,389,276
– –
2024 Q1
3 quarters
IMNM icon
15
Immunome
IMNM
$2.07B
$41.2M 1.56%
3,879,415
– –
2023 Q4
4 quarters
TECX icon
16
Tectonic Therapeutic
TECX
$417M
$39.2M 1.48%
849,143
– –
2024 Q2
2 quarters
TNGX icon
17
Tango Therapeutics
TNGX
$3.75B
$32.8M 1.24%
10,630,736
-2,700,000
-20% -$12.5M
2020 Q3
17 quarters
THRD icon
18
DELISTED
Third Harmonic Bio
THRD
$32.7M 1.24%
3,182,444
– –
2023 Q1
7 quarters
KURA icon
19
Kura Oncology
KURA
$874M
$31M 1.17%
3,557,269
-2,249,602
-39% -$32.4M
2015 Q4
36 quarters
NGNE icon
20
Neurogene
NGNE
$431M
$29.1M 1.1%
1,271,342
– –
2023 Q4
4 quarters
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.17B
$27.6M 1.04%
3,418,068
– –
2020 Q2
18 quarters
ETON icon
22
Eton Pharmaceutcials
ETON
$1.52B
$24.4M 0.92%
1,829,603
+1,263,528
+223% +$12.8M
2024 Q3
1 quarter
MBX icon
23
MBX Biosciences
MBX
$2.36B
$23.2M 0.88%
1,259,273
+83,464
+7% +$1.78M
2024 Q3
1 quarter
MDGL icon
24
Madrigal Pharmaceuticals
MDGL
$10.4B
$23.1M 0.87%
75,000
– –
2024 Q1
3 quarters
VYGR icon
25
Voyager Therapeutics
VYGR
$132M
$22.2M 0.84%
3,917,546
– –
2021 Q3
13 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2024 Portfolio in Review

As of Q4 2024, EcoR1 Capital held 75 positions worth $2.65B, down 9.5% from $2.92B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital withdrew a net $110M in Q4 2024, closing 16 positions and reducing 10 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $51.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in Sarepta Therapeutics worth $93.6M.

  • EcoR1 Capital's largest Q4 2024 buy was Sarepta Therapeutics: 770,000 shares worth $93.6M.
  • EcoR1 Capital added most to Zymeworks in Q4 2024, an estimated $22.2M increase.
  • EcoR1 Capital's biggest Q4 2024 reduction was Kura Oncology, cutting an estimated $32.4M.
  • EcoR1 Capital fully exited Centessa Pharmaceuticals in Q4 2024, selling an estimated $51.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.65B portfolio in Q4 2024.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q4 2024.
  • EcoR1 Capital's portfolio value fell 9.5% quarter-over-quarter to $2.65B.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.